Puma Biotechnology, Inc. PBYI

PBYI Company Overview

Puma Biotechnology, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for cancer treatment, with a primary emphasis on breast cancer. The company operates within the biotechnology and oncology pharmaceutical industries and generates most of its revenue from sales of its lead commercial product, NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for certain HER2-positive breast cancer indications. Puma Biotechnology also pursues clinical development programs involving neratinib in additional tumor types and combination therapies.

The company was founded in 2010 by Alan H. Auerbach following the acquisition of rights to neratinib from Pfizer. Since its formation, Puma Biotechnology has evolved from a development-stage biotechnology company into a commercial-stage oncology company with regulatory approvals in the United States and select international markets. Its strategic positioning is centered on targeted cancer therapeutics, particularly in HER2-driven cancers, supported by intellectual property rights, commercialization infrastructure, and oncology-focused clinical expertise.